[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"stage-ia-non-small-cell-lung-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:stage-ia-non-small-cell-lung-cancer":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,52],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100054190","segmentectomy-versus-lobectomy-for-deep-solid-dominant-early-stage-nsclc-100054190",false,"NCT07698990","Segmentectomy Versus Lobectomy for Deep Solid-Dominant Early-Stage NSCLC","Comparison of Segmentectomy and Lobectomy for Deeply Located, Solid-Dominant Early-Stage Non-Small Cell Lung Cancer (\u003C=2 cm): A Multicenter, Open-Label, Phase III, Randomized, Controlled, Non-Inferiority Clinical Trial","SOLID","Inclusion Criteria:\n\n1. Age 18 to 80 years.\n2. Solitary pulmonary nodule with maximum diameter \\\u003C=2 cm confirmed by preoperative thin-slice CT (\\\u003C=1 mm) and 3D reconstruction.\n3. Solid-dominant nodule with consolidation-to-tumor ratio (CTR) \\>0.5, including pure-solid nodules.\n4. Deeply located lesion, defined as the lesion center located in the inner two-thirds of the lung field on axial, coronal, and sagittal MPR images.\n5. Clinically definite suspected primary NSCLC after complete preoperative work-up and MDT discussion, with estimated malignancy probability \\>=95%. Preoperative pathologic confirmation is not mandatory, but preoperative or intraoperative pathology should be obtained when technically safe and feasible.\n6. Complete staging with thin-slice contrast-enhanced chest CT, whole-body PET-CT, brain contrast-enhanced MRI or CT, and serum tumor markers as appropriate; clinical stage IA (cT1a-bN0M0) without regional nodal or distant metastasis.\n7. Cardiopulmonary function sufficient to tolerate both lobectomy and segmentectomy, with FEV1 and DLCO \\>=60% predicted.\n8. Written informed consent, including special disclosure that final pathology may be benign.\n9. Centralized imaging review confirmation by the lead-center technical committee before randomization.\n\nExclusion Criteria:\n\n1. Lesion located in the right middle lobe.\n2. Lesion located in the inner two-thirds but adjacent to the lung apex or base and judged suitable for wedge resection.\n3. Two or more lesions requiring anatomic resection. One secondary lesion requiring only non-anatomic wedge resection is allowed; two main lesions in the same segment are excluded.\n4. Prior ipsilateral lung surgery or another malignancy within 5 years.\n5. Severe cardiovascular or cerebrovascular disease or other comorbidity making lobectomy or conversion to lobectomy intolerable.\n6. Planned basal segmentectomy (S7-10); proper segmentectomy is permitted.","ALL","18 Years","80 Years",{"count":21,"type":22},1200,"ESTIMATED","INTERVENTIONAL",[25],"NA","SOLID is a multicenter, open-label, randomized, controlled, phase III non-inferiority trial comparing anatomic segmentectomy with lobectomy in patients with deeply located, solid-dominant, clinical stage IA non-small cell lung cancer (NSCLC) measuring \\\u003C=2 cm. Eligible participants will undergo centralized imaging review and will be randomized preoperatively in a 1:1 ratio before induction of anesthesia.\n\nThe primary endpoint is 5-year overall survival. The key supportive secondary endpoint is 5-year recurrence-free survival. The study will enroll 1,200 participants and will use intention-to-treat analysis for the primary endpoint. An independent Data and Safety Monitoring Board and an independent Endpoint Adjudication Committee will oversee safety, surgical quality, data quality, and endpoint adjudication.",[28,29],"Non-Small Cell Lung Cancer","Stage IA Non-Small Cell Lung Cancer",[31,32,33,34,35,36,37,38],"segmentectomy","lobectomy","deep pulmonary nodule","solid-dominant nodule","early-stage NSCLC","non-inferiority trial","overall survival","recurrence-free survival","NOT_YET_RECRUITING","2026-07-07",{"date":42,"type":43},"2026-07-13","ACTUAL",{"date":45,"type":22},"2026-07",{"date":47,"type":22},"2034-07",{"name":49,"class":50},"Shanghai Chest Hospital","OTHER",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":62,"conditions":63,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":4,"leadSponsor":74,"locationsCount":51},"100178275","biomarkers-in-predicting-treatment-response-in-samples-from-patients-with-early-stage-non-small-cell-lung-cancer-previously-treated-with-adjuvant-chemotherapy-100178275","NCT01595074","Biomarkers in Predicting Treatment Response in Samples From Patients With Early-Stage Non-Small Cell Lung Cancer Previously Treated With Adjuvant Chemotherapy","The Identification, Validation and Implemention of Prognostic and\u002For Predictive Biomarkers for Adjuvant Chemotherapy in Early Stage Non-Small Cell Lung Cancer (NSCLC)","Inclusion Criteria:\n\n* Samples from patients treated in 4 adjuvant chemotherapy (ACT) for early-stage non-small cell lung cancer (NSCLC) pivotal trials:\n\n  * International Adjuvant Lung Cancer Trail (IALT)\n  * Cancer and Leukemia Group B (CALGB)-9633\n  * CAN-NCIC-BR10\n  * Adjuvant Navelbine International Trialist Association (ANITA)\n* Not specified\n* See Disease Characteristics",{"count":60,"type":22},950,"OBSERVATIONAL","This research trial studies biomarkers in predicting treatment response in samples from patients with early-stage non-small cell lung cancer previously treated with adjuvant chemotherapy. Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment.",[64,65,66,67,68],"Stage IA Non-small Cell Lung Cancer","Stage IB Non-small Cell Lung Cancer","Stage IIA Non-small Cell Lung Cancer","Stage IIB Non-small Cell Lung Cancer","Stage IIIA Non-small Cell Lung Cancer","2013-09-19",{"date":71,"type":22},"2013-09-20",{"date":73,"type":4},"2012-05",{"name":75,"class":76},"National Cancer Institute (NCI)","NIH"]